Vogenx Posts $4.9M Q3 Loss, But $3.4M Warrant Charge Skews the Number
VOGX sits 35% above its 52-week low of $12.95.
Summary
Vogenx's first quarterly report as a public company shows a Q3 net loss of $4.9M versus $284.4K a year earlier, or 47 cents a share, but $3.4M of that is a non-operating warrant fair-value charge, so the headline loss overstates operating expense growth. Liquidity is the real story: cash and marketable securities stood at $82.1M on September 30 versus $0.6M in cash at December 31, 2025, reflecting the August IPO that raised $81.25M gross plus a $12.2M over-allotment. The company initiated the EMERGE Phase 2b study in October with no efficacy data yet reported. This follows the September 10-Q that disclosed material weaknesses in internal controls and a restatement of prior financials, so reporting quality remains a live issue. EMERGE topline results are expected in H2 2027, with a gastroparesis Phase 2 study planned for H1 2027.
At the time of this announcement, VOGX was trading at $17.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $270.8M. The 52-week trading range was $12.95 to $38.41. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.